Positive Bioscience announced today
the launch of its next generation product, Positive Select, a RNA sequencing
test for Cancer treatment. Positive Select is the latest arsenal in fighting
against cancer and is intended to aid Oncologists select the best treatment for
cancer patients. Positive Select is based on whole RNA sequencing which is the
latest technology available in the world and enhances the utility of
comprehensive genomics profile manifold bringing Genomics test closer to
clinical practice. With this Positive Bioscience becomes the first company in
India to offer whole RNA sequencing test commercially for cancer.
“By
launching Positive Select, Positive Bioscience is again demonstrating its
commitment to innovation and making cutting edge molecular information
available to oncology community in India and worldwide,” said Samarth Jain,
Chief Executive Officer, Positive Bioscience. “Cancer is driven by genomic
alterations. Positive Select detects genomic alterations in all 25,000 genes
and recommends treatment options with best probability of response as compared
to recommendations based on testing of 4-5 genes through conventional testing.
We expect that Positive Select will revolutionise molecular diagnostics in a
way CT scan revolutionised imaging diagnostics when X Ray was a norm.”
"In
this era of Precision Oncology, RNA sequencing is a recent advancement in
diagnostic technology, offering the most comprehensive genetic information on
various alterations and the level of expression on thousands of genes in a
single step. The information can be used to select the best treatment option
with least side effects. Said "Dr Amit Verma, Consultant - Molecular
Oncology & Cancer Genetics, Max Super Speciality Hospitals Saket, New
Delhi.
About
Positive Select:
Positive
Select is a comprehensive genomic solution for solid tumours(Lung Cancer,
breast Cancer, Ovarian Cancer, Prostate Cancer, Sarcoma etc) as well as
Haematological cancers(leukaemia, lymphoma, myeloma) designed to provide
oncologists with clinically actionable report which can identify the molecular
alterations in a patient's tumour and match those alterations with relevant
targeted therapies and clinical trials.
The test
employs RNA sequencing to detect all classes of genomic alterations, including
base pair substitutions, insertions and deletions, copy number alterations and
rearrangements, and gene fusions.
Positive
Select test results are provided in an easy-to-interpret report supported by a
comprehensive review of published literature. Report provides treatment options
with best probability of working in a particular patient based on cancer
driving pathways and information on on-going clinical trials. Report also come
with expression data of around 25,000 genes and thus is the most advanced test
available in the world.
“RNA
sequencing is fast replacing conventional molecular diagnostics globally and
most of the leading cancer hospitals and academic institutes in USA have
started using RNA sequencing in clinical practice. It is a major step up as it
removes conventional trial and error treatment approach leading to better
outcomes and huge savings in treatment cost. Our experiences have showed that
RNA sequencing in cancer can reduce treatment costs by 35%,” added Dr Santosh
Mishra, Director of Bioinformatics, VGTI, Florida, USA and Scientific Advisor,
Positive Bioscience.
Positive
Select will be available in all leading hospitals of the country on a
prescription of Oncologists. For more information please visit www.positivebioscience.com or call
1800 3070 6727
About
Positive Bioscience:
Positive
Bioscience is India's leading clinical genomics company using big data and
artificial intelligence to predict disease risk in healthy individuals and best
treatment options in cancer patients. Positive Bioscience believes in providing
world-class molecular genetic testing and markets tests in Cancer Genomics
which are targeted for guiding treatment in cancer patients and Personal
Genomics tests which are targeted to healthy individuals for predicting disease
risk and preventing it.
Started in
October 2012 by Samarth Jain Positive Bioscience always brought the latest
genomics technology in India. It launched India’s first comprehensive cancer
genomics test in 2014. It also opened India’s first Personal Genomics clinic in
Medanta, The Medicity in August 2014. Company also is the first to
commercialize Whole Genome Sequencing for personal Genomics and circulating
tumour DNA test in cancer genomics. Positive Bioscience is also an exclusive
partner of Myriad Genetics USA, world’s leading molecular diagnostics company
well known for inventing BRCA gene testing.
All the
tests are carried out in NABL/CAP/CLIA accredited laboratories in India, USA,
China or Korea. For more information please visit www.positivebioscience.com or call
1800 3070 6727
No comments:
Post a Comment